{
  "trial_id": "NCT01945619",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant",
      "label": "unknown"
    },
    {
      "criterion": "CMV, adenovirus or EBV infection persistent despite standard therapy",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Received ATG, or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment.",
      "label": "triggers"
    },
    {
      "criterion": "Uncontrolled infections",
      "label": "unknown"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "8",
    "trial_id": "NCT01945619",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}